R & D

R & D background

R & D pipeline

UP818

Montelukast sodium

Intellectual Property

Home page

R & D background

R & D pipeline

Two projects are in clinical trial stage:

UP818

UP818, a new chemical entity with new mechanism, is intended to be used for Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) by i.v. and for Idiopathic Pulmonary Fibrosis (IPF) by s.c. Phase I study of i.v. on healthy volunteers in Hua Shan Hospital, Shanghai, China, is completing by the end of 2022. Phase II study on ARDS is planning to start in May, 2023. It is planning to submit CTA to Swedish MPA in June, 2023 and start clinical trial phase I in September, 2023, in Sweden.

Montelukast sodium

Montelukast sodium topical sterile gel for anorectal surgery and radiation proctitis. China mainland has been licensed to Shanghai Pharma, who is the sponsor for clinical trial and further development. Phase I study on healthy volunteers has been completed. Phase II studies on the two indications are planning to start in January and February, 2023.

Intellectual Property

12 patent applications by PCT

Number

First Submission Date

Application No

2017/07/05

PCT/CN2018/094441

2019/01/10

PCT/CN2020/071337

2021/08/06

PCT/CN2018/111247

2018/09/14